AS Latvijas Juras medicinas centrs Valuation

Q: What is the Fair Price of LJM1R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

LJM1R (€6.95) is trading above our estimate of [[fair value]] (€2.32)

Is LJM1R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LJM1R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LJM1R (€6.95) is trading above our estimate of fair value (€2.32)

Significantly Below Fair Value: LJM1R is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LJM1R?

Key metric: As LJM1R is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LJM1R. This is calculated by dividing LJM1R's market cap by their current revenue.
What is LJM1R's PS Ratio?
PS Ratio	0.5x
Sales	€10.20m
Market Cap	€5.36m

LJM1R key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	10.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LJM1R's PS Ratio compare to its peers?

The above table shows the PS ratio for LJM1R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2x
539428 Tejnaksh Healthcare	4x	n/a	₹505.6m
SSY SunLink Health Systems	0.2x	n/a	US$5.3m
AATMAJ Aatmaj Healthcare	3.7x	n/a	₹576.3m
EIF MedNation	0.1x	n/a	€4.5m
LJM1R AS Latvijas Juras medicinas centrs	0.5x	n/a	€5.4m

Price-To-Sales vs Peers: LJM1R is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does LJM1R's PS Ratio compare vs other companies in the European Healthcare Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LJM1R is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is LJM1R's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LJM1R PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LJM1R's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.